Navigation Links
Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will make a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy with Sindbis" at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks' presentation will take place on Wednesday, June 3, 2009 at 10:00 a.m. local time, in Shanghai China. Additional information about the conference can be found at: www.bio-forum.com.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.


'/>"/>
SOURCE Cynvec LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
2. Cynvec to Present at the BIO National Venture Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. ViroPharma to Present at Two June Healthcare Conferences
7. Cynosure Announces Presentations at Upcoming Investor Conferences
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
10. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):